A new study that uses an integrated single-cell transcriptomics approach to characterize cancer stem cell populations during treatment with molecularly targeted therapies offers insights into disease evolution and points to new therapeutic targets.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pattabiraman, D.R. & Weinberg, R.A. Nat. Rev. Drug Discov. 13, 497–512 (2014).
Valent, P. et al. Nat. Rev. Cancer 12, 767–775 (2012).
Giustacchini, A. et al. Nat. Med. 23 692–702 (2017).
O'Hare, T., Zabriskie, M.S., Eiring, A.M. & Deininger, M.W. Nat. Rev. Cancer 12, 513–526 (2012).
Hochhaus, A. et al. N. Engl. J. Med. 376, 917–927 (2017).
Corbin, A.S. et al. J. Clin. Invest. 121, 396–409 (2011).
Ellsworth, D.L. et al. Clin. Transl. Med. 6, 15 (2017).
Warfvinge, R. et al. Blood 129, 2384–2394 (2017).
Hanahan, D. & Coussens, L.M. Cancer Cell 21, 309–322 (2012).
The Cancer Genome Atlas Research Network. Nature 511, 543–550 (2014).
Cancer Genome Atlas Research N. Engl. J. Med. 368, 2059–2074 (2013).
Maheswaran, S. & Haber, D.A. Curr. Opin. Genet. Dev. 20, 96–99 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.J.D. is currently principal investigator or co-investigator on Novartis and Bristol-Myers Squibb clinical trials. His institution, OHSU, has contracts with these companies to pay for patient costs, nurse and data-manager salaries, and institutional overhead. He does not derive a salary, and his lab does not receive funds from these contracts. OHSU and B.J.D. have a financial interest in MolecularMD, a company that may have a commercial interest in this research and technology. This potential individual and institutional conflict of interest has been reviewed and managed by OHSU.
Rights and permissions
About this article
Cite this article
Eide, C., Druker, B. Understanding cancer from the stem cells up. Nat Med 23, 656–657 (2017). https://doi.org/10.1038/nm.4353
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4353